Luke A. Masterson

1.8k citations

30 papers · 856 indexed · h-index 16

Oncology top 5%
Radiology, Nuclear Medicine and Imaging top 5%
Molecular Biology
Organic Chemistry top 10%
Immunology

Co-authors: Philip W. Howard John A. Hartley Arnaud Tiberghien David G. Williams Lauren Adams David E. Thurston Simon Corbett Neki V. Patel
Topics: Synthesis and pharmacology of benzodiazepine derivatives (15 papers)HER2/EGFR in Cancer Research (13 papers)Cancer Treatment and Pharmacology (10 papers)
Cited by: Oncology Radiology, Nuclear Medicine and Imaging Organic Chemistry
Journals: Blood Analytical Chemistry Cancer Research
Partner nations: United Kingdom United States Germany

In The Last Decade

Luke A. Masterson

30 papers receiving 804 citations

Peers

Countries citing papers authored by Luke A. Masterson

Since Specialization

Citations

This map shows the geographic impact of Luke A. Masterson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luke A. Masterson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luke A. Masterson more than expected).

Fields of papers citing papers by Luke A. Masterson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luke A. Masterson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luke A. Masterson. The network helps show where Luke A. Masterson may publish in the future.

Co-authorship network of co-authors of Luke A. Masterson

This figure shows the co-authorship network connecting the top 25 collaborators of Luke A. Masterson. A scholar is included among the top collaborators of Luke A. Masterson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luke A. Masterson. Luke A. Masterson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Extensive Biotransformation Profiling of AZD8205, an Anti-B7-H4 Antibody-Drug Conjugate, Elucidates Pathways Underlying Its Stability In Vivo 2024 ·Analytical Chemistry ·Yue Huang,(unknown),Jiaqi Yuan,(unknown),(unknown),Kathryn Ball,Balakumar Vijayakrishnan,Luke A. Masterson,Krista Kinneer,Nadia Luheshi,Meina Liang,Anton I. Rosenbaum	9
2	Integrin-αvβ6 targeted peptide-toxin therapy in a novel αvβ6-expressing immunocompetent model of pancreatic cancer 2024 ·Pancreatology ·Nicholas F. Brown,Elizabeth Murray,(unknown),Philip W. Howard,Luke A. Masterson,Francesca Zammarchi,John A. Hartley,Patrick H. van Berkel,John F. Marshall	5
3	Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody–Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer 2022 ·Molecular Cancer Therapeutics ·Stephen J. Gregson,(unknown),Neki V. Patel,(unknown),Balakumar Vijayakrishnan,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Lauren Adams,Conor S. Barry,Kathryn Ball,Luke A. Masterson,Mary McFarlane,John A. Hartley,Philip W. Howard	4
4	Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus 2020 ·Theranostics ·Kate M. Moore,Ami V. Desai,Beatriz de Luxán‐Delgado,Sara Maria David Trabulo,(unknown),Nicholas F. Brown,Elizabeth Murray,Adam R. Brentnall,Philip W. Howard,Luke A. Masterson,Francesca Zammarchi,John A. Hartley,Patrick H. van Berkel,John F. Marshall	37
5	Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual β-glucuronide and dipeptide triggers 2019 ·European Journal of Medicinal Chemistry ·Stephen J. Gregson,Allison Barrett,Neki V. Patel,(unknown),Davide Schiavone,Erin Sult,Conor S. Barry,Balakumar Vijayakrishnan,Lauren Adams,Luke A. Masterson,François D’Hooge,M. L. Snaith,Jay Harper,John A. Hartley,Philip W. Howard	16
6	Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer 2019 ·mAbs ·Jason B. White,Ryan Fleming,Luke A. Masterson,(unknown),Haihong Zhong,Christine Fazenbaker,(unknown),Kim Rosenthal,(unknown),Vanessa Muniz‐Medina,Philip W. Howard,Rakesh Dixit,Herren Wu,Mary Jane Hinrichs,Changshou Gao,Nazzareno Dimasi	17
7	SLC46A3 as a Potential Predictive Biomarker for Antibody–Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads 2018 ·Clinical Cancer Research ·Krista Kinneer,John Meekin,Arnaud Tiberghien,Yu‐Tzu Tai,Sandrina Phipps,Christine Mione Kiefer,Marlon C. Rebelatto,Nazzareno Dimasi,Alyssa Moriarty,Kyriakos P. Papadopoulos,Sriram Sridhar,Stephen J. Gregson,Michael J. Wick,Luke A. Masterson,Kenneth C. Anderson,Ronald Herbst,Philip W. Howard,David A. Tice	58
8	Synthesis of a heterotrifunctional linker for the site-specific preparation of antibody-drug conjugates with two distinct warheads 2018 ·Bioorganic & Medicinal Chemistry Letters ·Amit Kumar,Krista Kinneer,Luke A. Masterson,(unknown),Philip W. Howard,Herren Wu,Changshou Gao,Nazzareno Dimasi	58
9	Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine 2018 ·Scientific Reports ·John A. Hartley,Michael Flynn,John P. Bingham,Simon Corbett,(unknown),Arnaud Tiberghien,Luke A. Masterson,Dyeison Antonow,Lauren Adams,(unknown),David G. Williams,Shenlan Mao,Jay Harper,Carin E.G. Havenith,Francesca Zammarchi,Simon Chivers,Patrick H. van Berkel,Philip W. Howard	85
10	Evaluation of Pyrrolobenzodiazepine-Loaded Nanoparticles: A Targeted Drug Delivery Approach 2018 ·Journal of Pharmaceutical Sciences ·Puneet Tyagi,Sergei Pechenov,Jonathan Rios‐Doria,Luke A. Masterson,(unknown),Philip W. Howard,Shenlan Mao,Jay Harper,Leslie Wetzel,(unknown),J. Anand Subramony	2
11	Characterization and in vitro data of antibody drug conjugates (ADCs) derived from heterotrifunctional linker designed for the site-specific preparation of dual ADCs 2018 ·Data in Brief ·Amit Kumar,Krista Kinneer,Luke A. Masterson,(unknown),Philip W. Howard,Herren Wu,Changshou Gao,Nazzareno Dimasi	3
12	Pyrrolobenzodiazepine Dimer Antibody–Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers 2017 ·Journal of Medicinal Chemistry ·Stephen J. Gregson,Luke A. Masterson,BinQing Wei,Thomas H. Pillow,Susan D. Spencer,(unknown),Shang‐Fan Yu,Helga Raab,Jeffrey Lau,Guangmin Li,Gail D. Lewis Phillips,Janet Gunzner-Toste,Brian S. Safina,Rachana Ohri,Martine Darwish,Katherine R. Kozak,Josefa dela Cruz-Chuh,Andrew G. Polson,John A. Flygare,Philip W. Howard	27
13	ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies 2016 ·Molecular Cancer Therapeutics ·Michael Flynn,Francesca Zammarchi,Peter Tyrer,Ayse U. Akarca,Narinder Janghra,(unknown),Carin E.G. Havenith,(unknown),Arnaud Tiberghien,Luke A. Masterson,Conor S. Barry,François D’Hooge,Teresa Marafioti,Paul W.H.I. Parren,David G. Williams,Philip W. Howard,Patrick H. van Berkel,John A. Hartley	85
14	Straightforward Glycoengineering Approach to Site-Specific Antibody–Pyrrolobenzodiazepine Conjugates 2016 ·ACS Medicinal Chemistry Letters ·Pamela Thompson,(unknown),Ian Hutchinson,Ryan Fleming,Binyam Bezabeh,(unknown),Shenlan Mao,Cui Chen,Luke A. Masterson,Haihong Zhong,Dorin Toader,Philip W. Howard,Herren Wu,Changshou Gao,Nazzareno Dimasi	28
15	SG2285, a Novel C2-Aryl-Substituted Pyrrolobenzodiazepine Dimer Prodrug That Cross-links DNA and Exerts Highly Potent Antitumor Activity 2010 ·Cancer Research ·John A. Hartley,(unknown),(unknown),(unknown),Marie Suggitt,Zhizhi Chen,Stephen J. Gregson,Luke A. Masterson,Arnaud Tiberghien,Janet M. Hartley,Chris Pepper,Thet Thet Lin,Chris Fegan,David E. Thurston,Philip W. Howard	43
16	Synthesis of a novel C2/C2′-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate 2009 ·Bioorganic & Medicinal Chemistry Letters ·Philip W. Howard,Zhizhi Chen,Stephen J. Gregson,Luke A. Masterson,Arnaud Tiberghien,(unknown),Min Fang,(unknown),(unknown),John A. Hartley,David E. Thurston	24
17	Design, Synthesis, and Biophysical and Biological Evaluation of a Series of Pyrrolobenzodiazepine−Poly(N-methylpyrrole) Conjugates 2006 ·Journal of Medicinal Chemistry ·Geoffrey Wells,(unknown),Philip W. Howard,Zara A. Sands,Charles A. Laughton,Arnaud Tiberghien,(unknown),Luke A. Masterson,(unknown),John A. Hartley,Terence C. Jenkins,Steven D. Shnyder,Paul M. Loadman,Michael J. Waring,David E. Thurston	67
18	Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy 2005 ·Bioorganic & Medicinal Chemistry Letters ·Luke A. Masterson,Victoria J. Spanswick,John A. Hartley,Richard H. J. Beǵent,Philip W. Howard,David E. Thurston	19
19	Synthesis and biological evaluation of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) C8 cyclic amine conjugates 2004 ·Bioorganic & Medicinal Chemistry Letters ·Luke A. Masterson,Stephen J. Croker,Terence C. Jenkins,Philip W. Howard,David E. Thurston	20
20	Approaches to Short-Acting Neuromuscular Blocking Agents: Nonsymmetrical Bis-tetrahydroisoquinolinium Mono- and Diesters 1996 ·Journal of Medicinal Chemistry ·(unknown),(unknown),Luke A. Masterson,John M. Midgley,J B Stenlake,William B. Wastila	7

About Luke A. Masterson

Luke A. Masterson is a scholar working on Oncology, Organic Chemistry and Immunology and Allergy, having authored 30 papers that have together received 856 indexed citations. Recurring topics across this work include Synthesis and pharmacology of benzodiazepine derivatives (15 papers), HER2/EGFR in Cancer Research (13 papers) and Cancer Treatment and Pharmacology (10 papers). The work is most often cited by research in Oncology (577 citations), Radiology, Nuclear Medicine and Imaging (397 citations) and Organic Chemistry (286 citations). Luke A. Masterson has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Philip W. Howard, John A. Hartley, Arnaud Tiberghien, David G. Williams, Lauren Adams, David E. Thurston, Simon Corbett, Neki V. Patel, Francesca Zammarchi and Nazzareno Dimasi. Their work appears in journals such as Blood, Analytical Chemistry and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact